Skip to main content
. 2019 Jul 17;2(4):247–263. doi: 10.1021/acsptsci.9b00020

Figure 2.

Figure 2

Combination treatment rescues more mis-splicing events in DM1 patient-derived myotubes than either drug alone. Splicing analysis of ES events determined via RNA-seq of non-DM control and DM1 myotubes treated with either 25 μM erythromycin (EM, green) or 0.5 μM furamidine (FM, blue) alone or a combination of both (EM+FM, magenta). The PSI values are shown for (A) ADD3 exon13 and (B) FN1 exon26 events. Mean % rescue ± standard deviation values are displayed below each graph. Both events display additive mis-splicing rescue after 4 days of treatment with the combination. (C) Global analysis of ES events that showed a greater than 10% change in PSI between non-DM control and DM1 myotubes were evaluated for mis-splicing rescue (p < 0.01, FDR < 0.1). The number of ES events that showed mis-splicing rescue (black bar) of > 10%, over-rescue (golden rod bar) of > 110% or mis-rescue (gray bar) of < −10% for each treatment are displayed. The average percent rescue for all “rescued” ES events for a given treatment is displayed above the black bar.